Evidence map›Paper›PMID 34060028›Full record

ReviewFolia microbiologica2021

Myxobacteria and their products: current trends and future perspectives in industrial applications.

Akansha Shrivastava, Rakesh Kumar Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Folia microbiologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Frontiers in microbiology · 2024
    Article
  3. Article
  4. Changes of endophytic microbial community inFrontiers in microbiology · 2022
    Article
  5. The Predatory MyxobacteriumMicroorganisms · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Akansha ShrivastavaDepartment of Biosciences, Manipal University Jaipur, Rajasthan, 303007, Jaipur, India.
Rakesh Kumar SharmaDepartment of Biosciences, Manipal University Jaipur, Rajasthan, 303007, Jaipur, India. rakeshkumar.sharma@jaipur.manipal.edu.ORCID http://orcid.org/0000-0002-2826-1291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxobacteria belong to a group of bacteria that are known for their well-developed communication system and synchronized or coordinated movement. This typical behavior of myxobacteria is mediated through secondary metabolites. They are capable of producing secondary metabolites belonging to several chemical classes with unique and wide spectrum of bioactivities. It is predominantly significant that myxobacteria specialize in mechanisms of action that are very rare with other producers. Most of the metabolites have been explored for their medical and pharmaceutical values while a lot of them are still unexplored. This review is an attempt to understand the role of potential metabolites produced by myxobacteria in different applications. Different myxobacterial metabolites have demonstrated antibacterial, antifungal, and antiviral properties along with cytotoxic activity against various cell lines. Beside their metabolites, these myxobacteria have also been discussed for better exploitation and implementation in different industrial sectors.

Indexed as

Industrial MicrobiologyMyxococcalesAnti-Bacterial AgentsAnti-Bacterial Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.